Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2013. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons under the GlaxoSmithKline 2009 Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity plan transactions.
Material Changes
On June 28, 2013, the Administrators of the 2009 Performance Share Plan notified the Company of increases in notional interests for various executives. These increases resulted from the notional re-investment of the dividend paid to shareholders on April 11, 2013. The transaction prices were 1565.50 pence per Ordinary Share and $48.52 per American Depositary Share (ADS).
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that notional dividends accrued will be paid out in proportion to the percentage of participants' Performance Share Plan holdings that vest following the end of the relevant three-year measurement period.
Important Facts for Investors to Verify
- The specific vesting schedules and conditions for the 2009 Performance Share Plan.
- The total number of shares or ADSs held by each notified executive prior to this transaction.
- The impact of the April 11, 2013 dividend on the overall equity structure.
- Compliance with Disclosure and Transparency Rule 3.1.4R(1)(a).